STUDresearch · Peptide
Apitegromab
Also known as
SRK-015 · apitegromab antibody
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Systemic
IV
Growth factors / muscle
Systemic anti-myostatin antibody.
What people say
A myostatin-targeting monoclonal antibody studied to improve muscle function in spinal muscular atrophy. It acts on pro/latent myostatin, not the androgen pathway; community interest is in useful function and muscle preservation, not an established gym effect.
Doses people talk about
SMA trial regimens on background therapy; no healthy-user or gray-market dosing protocol is established.
How it may feel
The reviewed SMA discussions describe hopes for small functional gains, not an immediate sensation. Public requests for trial experiences did not establish a dose-day or wear-off pattern; months-scale trial scores are a different endpoint.
SMA trial arms10 / 20 mg/kg IV every 4 weeks
12 months; ages 2–12 studied at 10 or 20 mg/kg, ages 13–21 at 20 mg/kg, with nusinersen or risdiplam.
Half-life & effect duration
- Half-life in the body
- IVAbout 24–31 days
- Felt duration people report
- Per-infusion durationNo consistent felt window reported
- Discussion focusSmall functional gains over longer treatment periods
Cycles people discuss
Repeated IV trial treatment runs for months, including every 4 weeks for 12 months in SAPPHIRE. Generic weeks-on/off and cost/caution chatter does not establish an apitegromab cycle.
Timing
Infusion appointments and clinical monitoring frame timing. The measured long serum half-life does not define when function improves, and training or sleep timing is not an established use pattern.
Stacks
Clinical add-on treatment with nusinersen or risdiplam is SMA-specific. It does not support bodybuilding combinations with other myostatin drugs, growth factors or research peptides.
Watch for
Seek care red flags: Severe allergic reaction, chest pain, neuro changes, or uncontrolled BP/glucose need real medical care — not forum advice.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
Mean apparent terminal half-life was 24–31 days after single IV doses in healthy adults.
The compound-specific phase 1 study used 1–30 mg/kg. Serum drug concentration is separate from latent-myostatin target engagement.
Not a class estimate, a gray-market formulation clock or evidence that functional benefit lasts 24–31 days.
- A randomized phase 1 safety, PK and PD study of apitegromab (2021) (opens in a new tab)Abstract, Methods, Results pharmacokinetics and Table 8 context, Discussion; full text read via Europe PMC fullTextXML after PMC CAPTCHA.Healthy-adult IV single-dose cohorts 1–30 mg/kg: mean apparent terminal half-life. Latent-myostatin target engagement is a different endpoint from felt benefit; not gray-market SC PK.
Felt duration people report
No dependable per-infusion felt duration was established in the public accounts reviewed.
SMA discussions express hopes for small functional gains; the trial's months-scale function endpoint is not a dose's perceptible active window.
No first-person dose/offset log in these visible threads. Private groups were not accessed; lack of a log here is not universal absence.
- How do you think our future will be like? — SMA treatment discussion (opens in a new tab)SKW_ofc OP and exchange with afro_mozart: hoped-for small functional improvements, limits from longstanding damage, apitegromab muscle versus neuronal-treatment distinction.Anticipation, not participants' treatment results. Numerical future hopes are not observed trial scores; no first-dose or post-dose duration established.
- Scholar Rock — public request for trial experiences (opens in a new tab)mrglorydays OP and kittenwalrus reply (June 28–July 1, 2026): asks for participants; respondent says not in trials and points to a Facebook group.Public thread did not supply a first-person treatment clock. Private Facebook content was not accessed; this bounded search does not imply experiences do not exist.
- SAPPHIRE phase 3 apitegromab trial (2025) (opens in a new tab)Complete indexed abstract, Methods and Findings: age-specific 10/20 mg/kg groups, every 4 weeks for 12 months, background SMN-directed treatment, HFMSE and adverse events.Nonambulatory SMA types 2/3, ages 2–21. Abstract only for this study; pooled-dose efficacy is not proof of each arm or healthy-user muscle growth.
Other context in this card
- Scholar Rock regulatory update, August 21, 2026 (opens in a new tab)Dated release headline and opening bullets: pending FDA decision/PDUFA, EU withdrawal/resubmission and Japanese submission plans.Sponsor account of regulatory status at that date, not regulator approval or a future guarantee. Used only to date the investigational pipeline framing.
What people say
- Body-comp talk: Apitegromab is discussed for recomp, strength continuity, or soft-tissue recovery depending on class. forum
- Training confound: PRs and scale changes almost always co-travel with diet phase and programming. anecdote
- Suppression / lipid chatter: Other hormonal agents in muscle-growth discussions bring bloodwork and PCT concerns even when called “mild.” That is not evidence that this myostatin-targeting antibody has an androgen-suppression/PCT profile. forum
- Cycle thinking: Fixed on/off blocks belong to broader self-experiment culture, not a demonstrated dominant apitegromab pattern. SMA research instead uses repeated interval dosing over months. forumtrial
- Motor function exploration: SMA and neuromuscular trial programs are the evidence core. trial
Doses people talk about
- Not gray-market daily pin culture. forum
- Schedule: multi-week IV intervals, not daily SC peptide culture. trial
- SMA trial amounts: ~10–20 mg/kg IV is the reported band; SAPPHIRE used 10 or 20 mg/kg every 4 weeks for 12 months in ages 2–12, and 20 mg/kg in ages 13–21, on background nusinersen or risdiplam. These are monitored trial arms, not healthy-user dosing. trial
- Framing: Anti-pro-myostatin monoclonal in SMA research. trial
How it may feel
- Days 1–7: The older site-reaction / GI / mood template described general injected or oral agents, not verified apitegromab experiences. Its clinical route is IV; the reviewed public discussions do not establish an oral effect pattern or an early subjective sequence. forumtrial
- Months-scale function: Clinical endpoints concern function over months. SMA community replies hope for small useful gains and note limits from longstanding damage; these are expectations, not reports of feeling an immediate muscle-growth effect. trialforum
- Day 1: Route, sting and GI logistics remain general notes, not a verified “most people” response to apitegromab. A public request for trial participants did not yield a first-person dose-day account in its visible replies. forum
- Days 2–7: A general side-effect observation window from the older notes, not an apitegromab-specific onset/offset finding; apparent benefits can be misattributed. forum
- Weeks 1–2: An early checkpoint in broader self-logs, not a validated apitegromab response timetable; the reviewed public threads do not establish one. forum
Cycles people discuss
- On/off discussion: Weeks-on / weeks-off, cost and caution remain in the older general self-protocol notes. Their prevalence or benefit for apitegromab is not established; they are distinct from months of scheduled IV trial treatment. forum
- No magic cycle: There is rarely one universal “correct” on/off calendar across forums. forum
- Interval dosing: Weeks between doses in trials. trial
- Reassess: Stop and reassess if adverse effects appear; this is not medical care. forum
Timing
- Timing practicalities: Clinical infusion visits and adverse effects are the relevant treatment logistics. Training/sleep timing in the older general self-experiment notes is not a verified apitegromab schedule. forumtrial
- PK versus response: Serum drug elimination and latent-myostatin target engagement were measured in phase 1; neither defines how long functional benefit is felt. The public SMA discussions reviewed here express hopes or request trial experiences, without a dependable per-infusion effect window. trialforum
- Measured apitegromab PK: In a healthy-adult phase 1 study, single IV doses of 1–30 mg/kg had mean apparent terminal half-lives of 24–31 days. This is drug-specific serum elimination, not a generic antibody-class estimate or a felt-benefit window. trial
More on what it is
- Research posture: Educational summary of public discussion and literature themes only. forum
- How people talk about it: Forum volume is a popularity signal for Apitegromab, not proof it works for you. forum
- What it is: Fully human monoclonal antibody targeting pro/latent myostatin activation, in clinical development for SMA / neuromuscular function; not a classic daily research-peptide vial. trial
- Context: Biopharma development, not a typical peptide-boutique product. The sponsor's August 21, 2026 update still described U.S. regulatory review and European resubmission plans; that is a dated pipeline status, not approval. trial
- Research only: Not approved advice for self-experimentation; legality and access vary by place. forum
Stacks
- Less is clearer: Solo runs make personal n=1 easier to interpret than five-compound blasts. forum
- Clinical combinations: SMA studies used apitegromab on background SMN-directed treatment, including nusinersen or risdiplam. That is disease-specific combination care, not evidence for a muscle-building peptide stack. trial
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- General caution: Research chemical and compounded sources vary; adverse events may be under-reported. forum
- Injection site (if injected): Redness, itch, lumps, bruise — technique and product quality matter. forum
- Unknowns: Long-term safety for gray-market preparations is often poorly characterized. forum
- Stack noise: Sides logged on multi-agent stacks cannot be blamed cleanly on one compound. forum
- Seek care red flags: Severe allergic reaction, chest pain, neuro changes, or uncontrolled BP/glucose need real medical care — not forum advice. forum
- Trial AE profile: SAPPHIRE listed fever, nasopharyngitis, cough, vomiting, upper respiratory infection and headache, with severity/incidence broadly similar between trial groups and no adverse-event discontinuations. That monitored SMA result is not proof of healthy-user or gray-market safety; follow publications/labeling as programs mature. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.